Department of Anesthesiology, Lanzhou Traditional Chinese Medicine Hospital of Orthopedics and Traumatology, Lanzhou, Gansu, China
Department of Anesthesiology, Lanzhou Traditional Chinese Medicine Hospital of Orthopedics and Traumatology, Lanzhou, Gansu, China.
BMJ Open. 2023 Jul 19;13(7):e072598. doi: 10.1136/bmjopen-2023-072598.
Perineural use of dexamethasone is demonstrated to extend the analgesia duration of peripheral nerve blocks (PNB), but its optimal dose remains unclear. This systematic review and meta-analysis aims to determine the optimal dose of perineural dexamethasone in the prolongation of analgesia for PNB.
PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and Web of Science will be searched from their inception to 1 March 2023. Language will be restricted to English. Randomised controlled trials that compared the efficacy and safety of different doses of perineural dexamethasone for PNB in adult patients will be included. Retrospective studies, reviews, meta-analyses, case reports, conference abstracts, comments and studies regarding paediatric surgeries will be excluded. The duration of analgesia will be defined as the primary outcome. Secondary outcomes will include pain scores, the total analgesic requirement over 48 hours and the incidence of adverse effects. Two reviewers will independently perform the study selection, data extraction and quality assessment. RevMan V.5.3 software will be used for data analysis. The quality of evidence will be assessed using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) approach.
No ethical approval is required. The results of this study will be submitted to peer-reviewed journals.
CRD42022385672.
研究表明,神经周围使用地塞米松可延长周围神经阻滞(PNB)的镇痛持续时间,但最佳剂量仍不清楚。本系统评价和荟萃分析旨在确定神经周围地塞米松在延长 PNB 镇痛中的最佳剂量。
将从建库起至 2023 年 3 月 1 日在 PubMed、EMBASE、Cochrane 中央对照试验注册库和 Web of Science 上进行检索。语言限制为英语。将纳入比较不同剂量神经周围地塞米松用于成人患者 PNB 的疗效和安全性的随机对照试验。将排除回顾性研究、综述、荟萃分析、病例报告、会议摘要、评论和儿科手术研究。镇痛持续时间将定义为主要结局。次要结局将包括疼痛评分、48 小时内的总镇痛需求以及不良反应的发生率。两名评审员将独立进行研究选择、数据提取和质量评估。RevMan V.5.3 软件将用于数据分析。使用推荐评估、制定与评价分级(GRADE)方法评估证据质量。
不需要伦理批准。本研究的结果将提交给同行评议的期刊。
PROSPERO 注册号:CRD42022385672。